Method for treatment of abdominal cavity primary and metastatic tumors
FIELD: medicine, oncology.
SUBSTANCE: method involves autoblood sample taking off in the amount 200-250 ml into a sterile flask with hemopreserving agent "Glugitsir" followed by centrifugation at 1500 rev/min for 30 min. Then supernatant plasma is placed into another sterile flask with a hemopreserving agent and cellular precipitate is reinfused. A single dose of a cytostatic agent is mixed with 10-100 ml of autoplasma, incubated at temperature 37°C for 1 h and administrated through catheter in abdominal cavity by puncture in lower quadrant of abdomen. Procedure is repeated if necessary. Method provides decreasing toxicity of chemotherapy, simple method and uniform distribution of volume of injected preparation for all abdomen cavity. Invention can be used in carrying out chemotherapy of abdomen cavity tumors with ascites.
EFFECT: improved method for treatment.
The invention relates to medicine, namely to Oncology, and can be used in chemotherapy of tumors of the abdomen, accompanied by ascites.
The known method of chemotherapy for ovarian cancer (Perevozchikova NI Chemotherapy of neoplastic diseases. Moscow, 2000. S), which consists in the introduction of intravenous cisplatin 100 mg/m2on day 1 and cyclophosphamide 600 to 750 mg/m21 day, the course can be repeated after 2 weeks. However, the application of this method of treatment is associated with severe toxic effects systemic effects of chemotherapy that requires a significant change in pay and course doses of cytostatics, the negative impact on the immune system of patients, prolongs the duration of treatment, requires massive accompanying therapy, affects the quality of life of patients.
Known "Method of chemotherapy for ovarian cancer (see ed. mon. No. 1693742 from 10.04.89, bull. No. 11, ed. Sidorenko US, Galatina LU), namely, that a massive infusion of chemotherapy drugs is carried out through the catheters introduced into the abdominal cavity during surgery, the proximal ends of which hang down into the abdominal cavity, and the distal ends remain on the skin of the abdomen for a long time. Microcatheters injected into the abdominal cavity during the operation with the two sides on the border of the anterior axillary line and 11th ribs that provide the characteristic swelling of chemotherapy through microcatheters from top to bottom, and irrigate the abdominal cavity. Chemotherapy should be performed within 7-10 days, a second course of treatment after 3 months in the same area. This improves the effectiveness of treatment and prolong the life of cancer patients.
However, this method requires surgical intervention for the production of the catheter, the presence of the bottom drainage opening from the vagina, involves the introduction of chemotherapy, the solutions of which are small amounts of liquid (cyclophosphamide, thiotepa, sarcolysin), which necessitates the installation of a catheter in the top floor of the abdominal cavity (2-3 cm below 11 ribs) to require the draining of the drug down and his contact with the abdominal cavity.
Known "Method of treatment of locally advanced breast cancer" (abstract. Diss. CMN the Vladimirova LU "Neoadjuvant chemotherapy on the natural environment of the organism with the use of the peptide of the epiphysis of epithalamin in treatment of locally advanced breast cancer". Rostov-on-don, 2000, S. 10), selected as a prototype, which is that collect autologous blood in quantities of 200 to 250 ml in a sterile vial geoconservation "Gleyzer", centrifuged at V. 1500 rpm, the supernatant plasma were evacuated to another sterile bottle with geoconservation. The cell sediment is re-infused. A single dose of RA drugs is tworay in 40 ml of physical the solution is mixed with 100 to 150 ml of autoplasma, incubated at 37 ° °C for 1 hour and injected intravenously 3 times a week. The method increases the effectiveness of the treatment, reducing tumor size, increased overall and relapse-free morbidity. However, he has expressed General toxic effects associated with systemic chemotherapy chemotherapy administration, and is not indicated for the treatment of abdominal tumors and ascites.
The aim of the invention is to increase the efficiency of treatment of patients with tumors of the abdomen, accompanied by ascites.
This objective is achieved in that the patient make the fence autologous blood in quantities of 200 to 250 ml in a sterile vial geoconservation "Gleyzer", centrifuged at V. 1500 Rev/min for 30 min, take the supernatant plasma in another sterile bottle with geoconservation, cellular precipitate is re-infused, single dose drugs mixed with 10-100 ml autoplasma, incubated at 37 ° °C for 1 hour and injected intraperitoneally through a catheter in the abdominal cavity, if necessary the procedure is repeated.
The invention of "a Method of treatment of tumors of the abdominal cavity is new, because it is not known from the level of medicine in the field of drug therapy in the sociology.
The novelty of the invention lies in the fact that the patient make the fence autologous blood in quantities of 200 to 250 ml in a sterile vial geoconservation "Gleyzer", centrifuged at V. 1500 rpm for 30 min, take the supernatant plasma in another sterile bottle with geoconservation, cellular precipitate is re-infused. A single dose of the chemical is mixed with 10-100 ml autoplasma, incubated at 37 ° °C for 1 hour and injected intraperitoneally through a catheter into the abdominal cavity through the puncture, if necessary the procedure is repeated.
The principal difference of this method of treatment used so far in Oncology is the introduction of drugs on autoplasma sobrepena, pioneered a new way of introduction autoplasma intraperitoneal. This avoids the need for Oceania drug down the puncture of the abdominal cavity and the establishment of the catheter in the top floor, because a sufficient volume of fluid injected intraperitoneally, and autoplasma achieved sufficient volume, and the product is evenly distributed in the abdominal cavity. In addition, we found that autoplasma is a modifier of action of chemotherapeutic agents, since their joint incubation is fragmented albumin, contributing to rapid flow of drugs into the tumor, and the e acquisition of fragments of albumin prooxidant properties, which reinforces the damaging effect of drugs on tumor cells.
Autoplasma - native biological environment for an organism, not an alien for intraperitoneal administration, does not cause a painful, inflammatory, other changes and complications of intraperitoneal injection.
Using this method does not increase the toxicity, if necessary, allows to combine intraperitoneal administration of cytostatics on autoplasma with standard chemotherapy.
A method of treating primary and metastatic tumors of the abdominal cavity is performed as follows.
A patient with a tumor of the abdomen, accompanied by ascites, in position on the back after percussion designated puncture to exclude the presentation of the colon perform the puncture of the anterior abdominal wall in place, typical parazette: in one of the lower quadrants (above the anterior iliac crest), lateral rectus, at the level of the navel or just below. After processing the puncture site with an antiseptic solution and anesthesia of the skin and the abdominal wall to the peritoneum solution of novocaine 0.25% or lidocaine 1% with a thick needle carry out the puncture. In the peritoneal cavity through the lumen of the needle conduct a thin plastic catheter with a diameter of 3 mm, Then pull the needle. The catheter may be tightened so that the cavity was up to 10 cm of the catheter is, the free end of the leave 3-6 refer to Evacuate ascitic fluid.
The patient produce the fence autologous blood in quantities of 200 to 250 ml sterile bottle geoconservation "Gleyzer", centrifuged at V about. 1500 Rev/min for 30 min, take the supernatant plasma in another sterile bottle with geoconservation, cellular precipitate is re-infused. A single dose of the cytostatic agent is mixed with 10-100 ml autoplasma, incubated at 37 ° °C for 1 hour. Then after sedation (analgin, Relanium) is injected through the catheter 0.25% solution of novocaine 20-40 ml) followed by the slow introduction of cytostatic agents on autoplasma. In the case of the use of cisplatin is intravenous drip water load up to 2-3 liters according to the conventional method, if necessary the procedure is repeated.
Examples of specific performance "method of treatment of tumors of the abdomen"
Example 1. Patient K., IB. No. 7871/0, 51 years, was in RNII treated with 8.05.02 on 24.06.02. Asked RNII with complaints of profuse watery vaginal discharge mixed with blood, pain in the lower abdomen on the left, constipation, rapid diuresis, the tumor in the right breast. Sick for 12 years, when the breast has been education. To doctors did not address. In April 2002, appeared above mentioned complaint from the genitals.
Objectively: the one integument pale gray color, right breast was purple in the outer squares rough tumor, up to 8 cm, axillary lymph nodes are palpable unclear. From respiratory and cardiovascular systems without pathology. The abdomen is enlarged, soft, palpation painful in hypogastrium, ascites. St. genitalis: the cervix is clean, the body of the uterus is normal in size, from the area of the left appendages comes tumor bumpy education, lower pole reaches back arch up to 15 cm in diameter.
When biopsy of the tumor mammary glands No. 1407-12 - moderately differentiated carcinoma. Ultrasound of abdominal organs from 10.05.02 marked increase in the epigastric lymph nodes up to 5×2 see ultrasound of the pelvic organs from 10.05.02 revealed the formation of the left ovary to 15 see the preliminary diagnosis: generalized cancer of the right breast with metastasis to the ovaries Art. IV. With 27.05. intraperitoneally introduced cisplatin 150 mg of cyclophosphamide 800 mg according to the described method. Of the side effects of nausea, vomiting II senior 18.06.02 introduction repeated. Upon completion of the course the patient's condition is satisfactory. The estimated effect regression of the tumor >50% and complete regression of retroperitoneal lymph nodes, confirmed by ultrasound. Complete resorption of ascites
23.06.02 - made supracervical amputation of the uterus with appendages, extirpation greater omentum. G.A. No. 648692-5 - in the left appendage: poorly differentiated serous adenocarcinoma, plots pappilary.
The final diagnosis: Primary multiple synchronous cancer: cancer of the right breast (T3N0M0) Article. III ovarian cancer with metastasis to the retroperitoneal lymph nodes, peritoneum, Art. IV ascites. Condition after combined treatment. Next, the patient continued chemo-and radiotherapy to the breast on the right.
Technical and economic efficiency "method of treatment of tumors of the abdominal cavity is to increase the efficiency of treatment of patients with tumors of the abdomen, accompanied by ascites due to application of autoplasma as a local modifier effects of chemotherapy. The method provides rapid tumor regression in 50% or more, does not increase the toxicity of chemotherapy that does not require additional expenses on the accompanying therapy, prolongs the life of patients with common cancers, improve their quality of life.
A method of treating primary and metastatic tumors of the abdomen, accompanied by ascites, including chemotherapy, characterized in that the patient make the fence autoblood in the amount of 200 to 250 ml in a sterile vial geoconservation "Gleyzer", centrifuged at 1500 rpm for 30 min, take the supernatant plasma in another sterile bottle with gameconsole is that the cell sediment is re-infused, a single dose of the cytostatic agent is mixed with 10-100 ml autoplasma, incubated at 37 ° °C for 1 h and injected intraperitoneally through a catheter into the abdominal cavity through a puncture in the lower quandrant belly, if necessary the procedure is repeated.
FIELD: medicine, oncology.
SUBSTANCE: invention relates to a method for treatment of malignant tumors. Method involves chemotherapy and hormonal therapy. Insulin of short action is administrated by subcutaneous injection in the dose 8-10 U as a hormone. In appearance of hypoglycemia symptoms chemopreparations are administrated in 200-250 ml of 40% glucose solution. Administration is carried out once time for 3-6 weeks by the known schedule. Method provides enhancing antitumor effect of chemopreparations due to reducing delivery of glucose into malignant cell, its energy deficiency and reducing adaptation ability to chemotherapy.
EFFECT: improved treatment method.
FIELD: medicine, immunology, oncology.
SUBSTANCE: invention relates to development of a method and composition promoting to enhancing absorption of immunocytokines in tumors. Compositions are based on combination of cytokine with agent enhancing absorption of immunocytokine. Invention provides the enhanced effectiveness of therapy of tumors and metastasis in mammals.
EFFECT: improved and valuable medicinal method of treatment.
27 cl, 10 dwg, 11 ex
FIELD: medicine, oncology, dermatology.
SUBSTANCE: the present innovation deals with treating mammalians due to introducing nonpsychotropic compounds - tetrahydrocannabinol derivatives, adjulemic acid derivative, in particular. The innovation suggested enables to either decrease or prevent cell proliferation at the following diseases: psoriasis, tumors along with low toxicity level of therapy conducted.
EFFECT: higher efficiency.
11 cl, 4 dwg, 1 ex, 2 tbl
FIELD: organic chemistry, chemical technology, medicine, pharmacy.
SUBSTANCE: invention relates to crystalline polymorphic modifications of strong acting epotilone analog of forma A and forma B represented by the formula (I): Invention proposes a crystalline substance representing a mixture of form A and form B of epotilone analogs. Invention proposes two variants of a method for preparing crystalline polymorphic modification representing form A. Also, invention proposes a pharmaceutical composition inhibiting angiogenesis and comprising an active component that represents crystalline polymorphic modification of epotilone analog of form A, form B or a crystalline polymorphic modification of epotilone analog of the formula (I) wherein this modification has no amorphous component, and a pharmaceutically acceptable carrier. Also, invention proposes a method for treatment of cancer comprising administration in mammal the effective dose of crystalline polymorphic modification of epotilone analog. Invention provides preparing crystalline polymorphic modifications of strong acting epotilone analog of the formula (I) characterizing by improved properties for using in therapy of cancer species.
EFFECT: improved preparing methods, valuable medicinal properties of compounds and composition.
16 cl, 9 dwg, 7 tbl, 5 ex
SUBSTANCE: method involves incubating antibiotics and/or chemopreparations in therapeutic doses with autoplasma 30 min at 37°C and introducing the preparations into paravaginal cellular tissue to patients suffering from genitalia diseases and into paravesical cellular tissue to patients suffering from urinary bladder diseases and into pararectal cellular tissue to patients suffering from rectum diseases. Tumor proliferation into neighboring small pelvis organs (into paravaginal and/or pararectal and/or paravesical cellular tissue) taking place, the treatment is applied twice a week.
EFFECT: increased pathological focus regression percent; reduced manifestations of drug therapy complications.
FIELD: medicine, in particular treatment of malignant neoplasm.
SUBSTANCE: claimed method includes administration of vaccine representing complex of heat shock protein and tumor peptide, isolated from subject tumor tissue, and radioactive preparation Oncofer. Oncofer is administered both during vaccination course and after vaccination.
EFFECT: stable antitumor immunity, enhanced tumor cell apoptosis and blocked blood supply due to alteration of erythrocyte properties in tumor caused by radioactive preparation and activation of clot formation in said vessels.
2 cl, 4 ex, 2 dwg
FIELD: medicine, oncology.
SUBSTANCE: invention relates to a method for treatment of malignant tumors. Method involves administration in a patient the chemotherapeutically active dose of antitumor platinum compound, foe example, cisplatin or carboplatin and erythropoietin or erythropoietin-like substance wherein the latter is administrated before administration of platinum compound or simultaneously with its. This method provides attaining the synergistic antitumor effect.
EFFECT: improved and valuable medicinal effect.
8 cl, 2 tbl, 2 dwg, 2 ex
FIELD: medicine, oncology, pharmacy.
SUBSTANCE: after proving the pleural fluid sterility method involves its exfusion from pleural cavity and administration of antitumor chemopreparations. Firstly, 20 mg of bleomycetin is incubated with 20 ml of autopleural fluid, pleural fluid remained after exfusion is placed into packages "Gemakon" and centrifuged at 2000 rev/min for 60 min and liquid part is frozen. Pleural fluid is removed again as its accumulation and administration of incubated mixture of pleural fluid with bleomycetin is repeated also wherein the bleomycetin dose is increased up to 25 mg. In 2-3 days after removal of pleural liquid chemopreparations incubated with preliminary defrosted liquid part of pleural fluid are administrated each 5-7 days in the following sequence and doses: the first administration - 100 mg of cisplatin; the second administration - 100 mg of cisplatin; third, fourth and fifth administrations - 30 mg of doxorubicin and 1000 mg of cyclophosphan up to the total amount - cisplatin, 200 mg; doxorubicin, 90 mg, and cyclophosphan, 3000 mg. Method provides elimination of pleural fluid in full volume, to compensate loss of liquid, protein and trace elements, to reduce tumor size and to avoid toxic symptoms of chemotherapy. Invention can be used in the presence of exudative pleuritis in patients with lung cancer who can't to be subjected for operative and radiation treatment.
EFFECT: improved treatment method.
FIELD: medicine, oncology.
SUBSTANCE: invention proposes using a medicine valsartan as an antagonist of AT-1 receptors and a modulator of AT-2 receptors in treatment of lung or mammary glands invasive cancer. All carcinomas comprise AT-2 receptors while in hyperplasia of normal epithelial cells AT-2 receptors are localized only. This allows carrying out both diagnosis of malignant tumor development and treatment indicated diseases with valsartan owing to modulation of AT-2 receptors, i. e. based on change of the host biological response for tumor cells.
EFFECT: improved and valuable medicinal properties of medicine agent.
13 tbl, 12 ex
SUBSTANCE: method involves taking blood from pulmonary artery in the amount of 400-600 ml into reservoir containing Glucigir as anticoagulant during operation after having ligated lung root blood vessels. Cysplatin in the amount of 50 mg/m2 and Doxorubicin in the amount of 50 mg/m2 are added and the mixture is hold for 30 min at 37°C and introduced to a patient in drip feed during continued surgical intervention.
EFFECT: combined specific antitumor treatment and nonspecific immune system stimulation; improved patient life quality.
FIELD: medical equipment.
SUBSTANCE: catheter has flexible catheter tube and device for controlled deviation of distal end part of catheter tube. Device for controlled deviation of distal end part of flexible catheter tube is made in form of wire conductor made of springing elastic material. Conductor is capable of free moving along catheter tube into neutral position or initial position. As a result, when conductor is more or less pulled in relatively its initial position, end part of flexible catheter tube does move. Conductor has twisted spiral-shaped end part which when being in neutral or initial position takes place directly in opposition to external end of catheter tube. As a result, when wire conductor is pulled in relatively its initial position inside flexible tube, the end part of tube deflects at adjusted angle under influence of compression power of twisted spiral-shaped end part, which straightens forcedly.
EFFECT: minimal invasive surgery; ability of controlling catheter tube outside patient's body.
5 cl, 2 dwg
SUBSTANCE: method involves carrying out thoracocentesis, introducing draining tube and fixing it in chest wall. The tube is fixed by introducing corrugated part of device for draining pleural cavity into trocar stiletto cylinder sleeve, moving it into the pleural cavity and fixing corrugation near costal part of parietal pleura. The device has trocar, draining tube, tubular pusher for moving the tube into the pleural cavity and external fixing member. The trocar is manufactured as stiletto having an enveloping cylinder sleeve. The draining tube has corrugation manufactured some distance away from draining tube end, the distance being equal to purulent cavity size determined in X-ray examination. The corrugation collapses when being introduced into the cylinder sleeve. The fixing member is manufactured as plate having a hole tightly embracing the draining tube.
EFFECT: enhanced effectiveness of treatment irrespectively of patient chest wall thickness; reliability and accuracy in tube fixation.
2 cl, 4 dwg
FIELD: medicine; medical engineering.
SUBSTANCE: device has catheter having internal canal, tube arranged in front of distal catheter end and fixing ligature. Reach-through holes are available in catheter wall for connecting the internal canal to environment medium. The fixing tube has reach-through hole in its wall. Intracorporal fixing ligature end is attached to distal end of the fixing tube. Extracorporal end of fixing ligature is introduced into internal canal of the fixing tube via the reach-through hole in fixing tube wall. Ligature is brought out via proximal fixing tube end, drawn through the internal catheter canal and brought out via proximal catheter end having sealing valve. Pusher having connection rod is detachable from the catheter. The fixing tube is shapable as loop holding the catheter in organ cavity. Method involves applying colonoscopy operation. The place intended for setting catheter being reached with endoscope, the fixing tube and catheter are pushed by catheter through instrumental endoscope canal into hollow organ with their distal ends forward. Pusher rod is inserted into proximal catheter end and catheter pushing through the endoscope canal goes on until the fixing tube and distal catheter end exit from endoscope canal into organ cavity. Then, the fixing ligature is pulled in holding the extracorporal end causing the fixing tube to bend as loop in intestine. The so formed loop is brought to the setting place. The loop is pressed against hollow organ wall and the endoscope is carefully withdrawn from the hollow organ. Pushing catheter into hollow organ lumen is kept on with pusher in concurrently slackening ligature out. The proximal catheter end is removed from the endoscope after withdrawing the endoscope from the organ. The pusher is detached from the catheter. Extracorporal fixing ligature end projecting from the proximal catheter end is caught and ligature slack is pulled up. Valve and catheter are attached to external catheter end. The external catheter end is fixed on body.
EFFECT: high accuracy in delivering drugs exactly to pathological focus.
11 cl, 4 dwg
SUBSTANCE: method involves introducing probe into the stomach via esophagus. Guiding probe in the stomach and intestine is carried out under laparoscopic control. After having placed the working end in the stomach, elastic conductor is introduced via its internal canal. Flexible tube is introduced as far as possible along the external surface into pyloric sphincter and is arranged on the stomach fundus on the greater curvature. Probe with conductor is introduced along the tube via the pyloric sphincter to duodenojejunal curve. The duodenojejunal curve angle is reduced in instrumental way and by turning the patient to the right side. The probe and conductor are brought behind the duodenojejunal curve by applying axial pressure to the external probe end.
EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.
FIELD: medicine, ophthalmology, pediatrics.
SUBSTANCE: method involves irrigation therapy (IT) by retrobulbar catheterization. Before carrying out IT the preparation "Ginkgo biloba" in capsules and age dosage and nasal drops "Semaks" by 1-2 drops for 1 month is prescribed to patient. Then in IT is carried out for 10 days in hospital by administration of cerebrolysin, riboflavin, agapurin, taufon and emoxipine in the dose 0.4 ml of each of them. Preparations are administrated successively, by fractional doses with interval for 2 h in combination with laser-pleoptic treatment at wavelength 0.63 mcm using device "SPEKL" for 10 min, by one procedure per a day for 10 days. After treatment in hospital glutamine and lecithin is prescribed by ambulatory treatment in age doses for 1 month. Method provides the prolonged remission of disease and reduced hospital period due to the complex effect of indicated curative factors on metabolism normalization in nervous cells, their resistance to stress injures, improvement of regenerative and microcirculating processes in eye tissues, frequency-contrast characterization of visual analyzer.
EFFECT: improved treatment method.
FIELD: medicine, surgery.
SUBSTANCE: method involves carrying out an antibacterial therapy and additional administration of curative mixture consisting of one part of dimexide, two parts of 0.5% of novocaine solution with antibiotic eliciting high the bacteriostatic activity against microflora in duct secret. Administration of this curative mixture is carried out by catheter into injured duct directly by course 1-2 times. Invention promotes to topical sanitation of mammary gland duct and reducing time of disease. Invention can be used in treatment of galactophoritis.
EFFECT: improved method for treatment.
FIELD: oncological diseases.
SUBSTANCE: invention is designed for use in complex treatment of urinary bladder cancer in case of propagation of tumor to sub-epithelium connective tissue. Method comprises transurethral resection and introduction of immune preparations and furacillin solution. Once transurethral resection completed, three-way Foli catheter is transurethrally introduced to patient, through which mixture of standard furacillin solution with 10·106 ME interferon α-2β is injected from the first postoperative day and over following 3-5 postoperative days bringing summary dose of interferon to 50·106 ME.
EFFECT: prevented traumatism of urinary bladder due to single introduction of catheter and assured continuous action of drugs without development of immune complications.
FIELD: medicine, oncology.
SUBSTANCE: the present innovation should be applied at adjuvant chemotherapy in case of tumors of central nervous system. Moreover, while carrying out lumbar puncture it is necessary to perform catheterization of subarachnoidal space. Moreover, one should daily sample liquor at the quantity of 10 ml to be incubated with chemopreparation in vitro for 30 min at 38 C. One should daily introduce chemopreparations upon autoliquor through catheter during the whole period of therapy course. The method enables to choose any mode and duration of endolumbar chemotherapy at its decreased toxicity.
EFFECT: higher efficiency of chemotherapy.
SUBSTANCE: method involves determining required foramen level. Needle is introduced at lumbar, sacral and thoracic segment level in paravertebral way with posterolateral access method and with anterolateral access at the cervical segment level. Tuochi 16-20 needle is applied. The needle is introduced 7-12 cm far from vertebral column median in the direction of intervertebral foramen at an angle of 50-80° to table surface in prone patient position at lumbar, sacral and thoracic segment level. The needle is brought in sliding in lateral direction after it has rested against joint facet. The needle is introduced towards the intervertebral foramen in dorsal patient position. Then, the needle slides from the transverse process in ventral direction. Short-term pain increase being the case, drugs are introduced.
EFFECT: enhanced effectiveness of treatment.
FIELD: medical equipment.
SUBSTANCE: device can be used for medicinal and donor blood separation to erythromass and plasma, for removal of plasma, return of erythromass to patient and introduction of plasma-substituting solutions and anticoagulant. Device has blood taking conduct provided with accumulating container, erythromass returning conduct with air trap, anticoagulant and hemodilution agent supplying conduct and plasma collecting conduct provided with removable containers and clamps. Blood taking conduct has injection unit for additional introduction of medicines, which unit is disposed close to needle for blood taking. Blood taking conduct is joined permanently with accumulating container which is made of film material. Accumulating container has additional tube provided with clamp. One end of tube is joined permanently with accumulating container and the other end is connected with connector and plug. Dropping bottles with polymeric two-channeled needles are mounted at hemodilutant agent and anticoagulant supply conducts. Plasma collecting conduct has container for collection plasma which container is made of film material. Polymeric needles at conducts for supplying hemodilution agent and anticoagulant are made with two channels. Extracorporal close circuit is made to provide higher sterility of plasmapheresis.
EFFECT: better comfort at operation; higher degree of sterility.
2 cl, 1 dwg